CKDXF (Opthea) 3-Year FCF Growth Rate : -33.10% (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Opthea 3-Year FCF Growth Rate?

Opthea's Free Cash Flow per Share for the six months ended in Jun. 2024 was $0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -33.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -57.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -28.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Opthea was 38.60% per year. The lowest was -146.80% per year. And the median was -24.20% per year.

Competitive Comparison of Opthea's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Opthea's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Opthea's 3-Year FCF Growth Rate falls into.

Opthea 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Opthea (OTCPK:CKDXF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Opthea 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Opthea's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (OTCPK:CKDXF) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany OPT:Australia

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.